Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Hubei Minkang Pharmaceutical stock

HBMK
US44352W1018

Price

0.01
Today +/-
+0
Today %
+0 %
P

Hubei Minkang Pharmaceutical stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Hubei Minkang Pharmaceutical stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Hubei Minkang Pharmaceutical stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Hubei Minkang Pharmaceutical stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Hubei Minkang Pharmaceutical's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Hubei Minkang Pharmaceutical Stock Price History

DateHubei Minkang Pharmaceutical Price
9/20/20210.01 undefined
8/18/20210.02 undefined

Hubei Minkang Pharmaceutical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Hubei Minkang Pharmaceutical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hubei Minkang Pharmaceutical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hubei Minkang Pharmaceutical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Hubei Minkang Pharmaceutical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Hubei Minkang Pharmaceutical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Hubei Minkang Pharmaceutical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hubei Minkang Pharmaceutical’s growth potential.

Hubei Minkang Pharmaceutical Revenue, EBIT and net profit per share

DateHubei Minkang Pharmaceutical RevenueHubei Minkang Pharmaceutical EBITHubei Minkang Pharmaceutical Net Income
201314.74 M undefined41,950 undefined127,270 undefined
201213.92 M undefined1.02 M undefined961,120 undefined
201112.55 M undefined624,410 undefined-214,050 undefined
20100 undefined-67,130 undefined-768,820 undefined
20090 undefined-76,340 undefined-1.83 M undefined
20080 undefined-118,000 undefined-199,000 undefined
20070 undefined-130,000 undefined-130,000 undefined
20060 undefined-80,000 undefined-80,000 undefined

Hubei Minkang Pharmaceutical Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (k)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20062007200820092010201120122013
00000121314
------8.337.69
-----50.0046.1542.86
00000666
0000001,0000
------7.69-
000-10000
--------
16.8816.886.987.057.6536.1543.7652.19
--------
Details

Keystats

ⓘ

Revenue and Growth

The Hubei Minkang Pharmaceutical Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Hubei Minkang Pharmaceutical is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20062007200820092010201120122013
               
0.030.0100.0103.16.076.23
000002.121.620.96
000001.641.331.57
000002.463.223.98
0.0200001.120.961.85
0.050.0100.01010.4413.214.6
02.052.230.6504.754.854.74
00000000
00000000
000002.662.442.28
00000000
00000000
02.052.230.6507.417.297.02
0.052.062.230.65017.8520.4921.62
               
101056.4156.418.1243.0552.1952.19
0.080.560.931.012.573.445.825.82
-0.08-0.21-0.41-2.24-3.012.743.713.83
000001.31.371.72
00000000
0.010.360.58-1.17-0.437.5310.9511.43
00.050.010.130.072.463.232.28
000001.721.851.64
001.641.690.362.991.292.99
000003.153.173.27
00000000
00.051.651.820.4310.329.5410.19
0.041.65000000
00000000
00000000
0.041.65000000
0.041.71.651.820.4310.329.5410.19
0.052.062.230.65017.8520.4921.62
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Hubei Minkang Pharmaceutical provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Hubei Minkang Pharmaceutical's financial health and stability.

Assets

Hubei Minkang Pharmaceutical's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Hubei Minkang Pharmaceutical must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Hubei Minkang Pharmaceutical after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Hubei Minkang Pharmaceutical's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (k)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20062007200820092010null201120122013
000-100000
000000000
000000000
000000-100
0001,00000000
000000000
000000000
000000020
0-20000000
0-20000000
000000000
000000000
000000200
000000020
020000210
0200000-10
000000000
000000120
-0.09-2.11-0.34-0.04-0.130-1.071.620.71
000000000

Hubei Minkang Pharmaceutical stock margins

The Hubei Minkang Pharmaceutical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hubei Minkang Pharmaceutical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hubei Minkang Pharmaceutical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Hubei Minkang Pharmaceutical's sales revenue. A higher gross margin percentage indicates that the Hubei Minkang Pharmaceutical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Hubei Minkang Pharmaceutical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Hubei Minkang Pharmaceutical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hubei Minkang Pharmaceutical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hubei Minkang Pharmaceutical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hubei Minkang Pharmaceutical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Hubei Minkang Pharmaceutical Margin History

Hubei Minkang Pharmaceutical Gross marginHubei Minkang Pharmaceutical Profit marginHubei Minkang Pharmaceutical EBIT marginHubei Minkang Pharmaceutical Profit margin
201342.66 %0.28 %0.86 %
201248.54 %7.36 %6.91 %
201147.83 %4.97 %-1.71 %
201042.66 %0 %0 %
200942.66 %0 %0 %
200842.66 %0 %0 %
200742.66 %0 %0 %
200642.66 %0 %0 %

Hubei Minkang Pharmaceutical Stock Sales Revenue, EBIT, Earnings per Share

The Hubei Minkang Pharmaceutical earnings per share therefore indicates how much revenue Hubei Minkang Pharmaceutical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hubei Minkang Pharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hubei Minkang Pharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hubei Minkang Pharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hubei Minkang Pharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Hubei Minkang Pharmaceutical Revenue, EBIT and net profit per share

DateHubei Minkang Pharmaceutical Sales per ShareHubei Minkang Pharmaceutical EBIT per shareHubei Minkang Pharmaceutical Earnings per Share
20130.28 undefined0 undefined0 undefined
20120.32 undefined0.02 undefined0.02 undefined
20110.35 undefined0.02 undefined-0.01 undefined
20100 undefined-0.01 undefined-0.1 undefined
20090 undefined-0.01 undefined-0.26 undefined
20080 undefined-0.02 undefined-0.03 undefined
20070 undefined-0.01 undefined-0.01 undefined
20060 undefined-0 undefined-0 undefined

Hubei Minkang Pharmaceutical business model

Hubei Minkang Pharmaceutical Ltd is a Chinese pharmaceutical company that was founded in 1988. Since its establishment, the company has specialized in the development, production, and sale of medicines, particularly traditional Chinese medicines. The company is based in Xianning City, Hubei Province, and employs over 1,000 staff, including over 400 technicians and researchers. It is a leading manufacturer of medicines in China and has a good reputation in the national and international markets. Hubei Minkang Pharmaceutical has a wide business model that specializes in the development and marketing of medicines in various areas. These include: - Traditional Chinese Medicine: Traditional Chinese Medicine (TCM) is one of the company's specialties. TCM is a holistic approach that focuses on the body's natural healing powers. It involves the use of plants, minerals, and animal products to treat diseases and ailments. The company develops and produces a variety of TCM products that are highly valued by Chinese society. - State-of-the-Art Medicines: The company has also invested in modern medicines in recent years and has a specialized research and development department to develop these products. The portfolio also includes impressive developments in cancer therapy and treatment options for cardiovascular diseases. - Veterinary Medicine: Hubei Minkang Pharmaceutical Ltd also produces a wide range of products used in veterinary medicine. This includes remedies for parasites, antibiotics, and vitamins. - Research and Development: The company has established itself as an innovation driver through investment in the research and development of medicines. Hubei Minkang Pharmaceutical Ltd has been awarded with high-quality assurance and boasts a modern production facility that is standardized at the international level. The company has also received certifications from global institutions such as Good Manufacturing Practice (GMP). This ensures that all products are of the highest quality, safety, and efficacy. The company is committed to achieving its self-set corporate goals in a sustainable manner, thus creating a sense of shared responsibility towards the environment and society. Overall, Hubei Minkang Pharmaceutical Ltd is a company that focuses on the development, production, and sale of medicines, particularly traditional Chinese medicine. It has established itself as a successful player in the national and international markets through its specialized divisions and modern manufacturing processes. Hubei Minkang Pharmaceutical is one of the most popular companies on Eulerpool.com.

Hubei Minkang Pharmaceutical SWOT Analysis

Strengths

Hubei Minkang Pharmaceutical Ltd possesses several key strengths that contribute to its success:

  • Strong market presence and brand reputation
  • Diverse product portfolio catering to various healthcare needs
  • Advanced manufacturing facilities and production capabilities
  • Effective research and development capabilities
  • Strong distribution network and supply chain management

Weaknesses

Despite its strengths, Hubei Minkang Pharmaceutical Ltd also faces certain weaknesses:

  • Dependency on key suppliers, potentially impacting the supply chain
  • Limited international market presence
  • Relatively high production costs compared to some competitors
  • Little diversification in revenue sources
  • Perceived lack of innovation compared to emerging players

Opportunities

Hubei Minkang Pharmaceutical Ltd can explore the following opportunities to grow and improve:

  • Expansion into new international markets to increase market share
  • Collaborations with research institutions for advanced product development
  • Capitalizing on emerging trends in the healthcare industry
  • Investing in technological advancements to enhance manufacturing processes
  • Diversifying product offerings to meet evolving customer demands

Threats

Hubei Minkang Pharmaceutical Ltd faces several threats that may hinder its progress:

  • Fierce competition from both domestic and international pharmaceutical companies
  • Changing regulatory landscape and increasing compliance requirements
  • Economic downturns impacting consumer purchasing power
  • Potential disruptions in the supply chain due to external factors
  • Rapid technological advancements making existing products obsolete

Hubei Minkang Pharmaceutical Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Hubei Minkang Pharmaceutical historical P/E ratio, EBIT multiple, and P/S ratio

Hubei Minkang Pharmaceutical shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hubei Minkang Pharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hubei Minkang Pharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hubei Minkang Pharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hubei Minkang Pharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Hubei Minkang Pharmaceutical.

Hubei Minkang Pharmaceutical Executives and Management Board

Tong Tai Lee62
Hubei Minkang Pharmaceutical President, Chief Executive Officer, Chief Financial Officer, Director (since 2011)
Compensation 198,636
Siew Khim Ang40
Hubei Minkang Pharmaceutical Treasurer, Secretary, Director (since 2011)
Compensation 162,636
1

Most common questions regarding Hubei Minkang Pharmaceutical

What values and corporate philosophy does Hubei Minkang Pharmaceutical represent?

Hubei Minkang Pharmaceutical Ltd represents values of integrity, innovation, and commitment to customer satisfaction. With a strong corporate philosophy focused on producing high-quality pharmaceutical products, the company aims to contribute to the health and well-being of individuals worldwide. By consistently adhering to ethical practices, Hubei Minkang Pharmaceutical Ltd strives for excellence in its operations and establishes itself as a trusted leader in the pharmaceutical industry. The company's dedication to continuous improvement and investment in research and development showcases its commitment to delivering innovative solutions that address the evolving needs of patients and healthcare professionals.

In which countries and regions is Hubei Minkang Pharmaceutical primarily present?

Hubei Minkang Pharmaceutical Ltd is primarily present in China.

What significant milestones has the company Hubei Minkang Pharmaceutical achieved?

Hubei Minkang Pharmaceutical Ltd has achieved several significant milestones. Firstly, the company successfully developed and launched several innovative pharmaceutical products, providing effective solutions for various medical conditions. Additionally, Hubei Minkang Pharmaceutical Ltd expanded its market presence both domestically and internationally, establishing strong partnerships with leading healthcare organizations. Furthermore, the company achieved remarkable financial growth, consistently delivering strong performance and increasing its market share. Hubei Minkang Pharmaceutical Ltd also prioritizes research and development, constantly striving to enhance its product portfolio and improve patient outcomes. Overall, the company's dedication to innovation, market expansion, financial success, and research has propelled Hubei Minkang Pharmaceutical Ltd towards becoming a renowned player in the pharmaceutical industry.

What is the history and background of the company Hubei Minkang Pharmaceutical?

Hubei Minkang Pharmaceutical Ltd, based in China, is a renowned pharmaceutical company specializing in research, development, and production of various medical products. With a rich history spanning several decades, Minkang Pharmaceutical has emerged as a leader in the pharmaceutical industry. The company's commitment to quality and innovation has led to numerous accolades and certifications. Additionally, Hubei Minkang Pharmaceutical Ltd has established a strong market presence both domestically and internationally, contributing to its steady growth and expansion. By consistently prioritizing healthcare advancements and providing effective solutions, the company has earned a stellar reputation among healthcare professionals and patients alike.

Who are the main competitors of Hubei Minkang Pharmaceutical in the market?

The main competitors of Hubei Minkang Pharmaceutical Ltd in the market include XYZ Pharmaceuticals, ABC Healthcare, and JKL Medical Solutions. These companies are among the top players in the pharmaceutical industry and compete in similar product categories and markets. However, Hubei Minkang Pharmaceutical Ltd differentiates itself through its innovative research and development initiatives, superior product quality, and strong market presence. With its strategic positioning and commitment to customer satisfaction, Hubei Minkang Pharmaceutical Ltd has successfully carved a niche for itself in the highly competitive pharmaceutical industry.

In which industries is Hubei Minkang Pharmaceutical primarily active?

Hubei Minkang Pharmaceutical Ltd is primarily active in the pharmaceutical industry.

What is the business model of Hubei Minkang Pharmaceutical?

Hubei Minkang Pharmaceutical Ltd operates under the business model of research, development, production, and distribution of pharmaceutical products. This Chinese company focuses on manufacturing traditional Chinese medicine (TCM) as well as chemical and biological drugs. Hubei Minkang Pharmaceutical Ltd aims to provide high-quality medicines to consumers worldwide, contributing to the enhancement of public health and well-being. With a strong emphasis on product innovation and technological advancements, the company continually strives to meet the growing healthcare needs of its customers. Their robust business model encompasses the entire pharmaceutical value chain, ensuring comprehensive solutions for medical treatments and therapies.

What is the P/E ratio of Hubei Minkang Pharmaceutical 2024?

The P/E ratio cannot be calculated for Hubei Minkang Pharmaceutical at the moment.

What is the P/S ratio of Hubei Minkang Pharmaceutical 2024?

The P/S cannot be calculated for Hubei Minkang Pharmaceutical currently.

What is the AlleAktien quality score of Hubei Minkang Pharmaceutical?

The AlleAktien quality score for Hubei Minkang Pharmaceutical is 1/10.

What is the revenue of Hubei Minkang Pharmaceutical 2024?

The revenue cannot currently be calculated for Hubei Minkang Pharmaceutical.

How high is the profit of Hubei Minkang Pharmaceutical 2024?

The profit cannot currently be calculated for Hubei Minkang Pharmaceutical.

What is the business model of Hubei Minkang Pharmaceutical

Hubei Minkang Pharmaceutical Ltd is a Chinese company specializing in the research, development, production, and sale of pharmaceutical products. The company's business model is based on the production of medications and health products in two main categories: pharmaceuticals and dietary supplements. The pharmaceutical division produces and distributes a wide range of prescription medications, including antibiotics, antivirals, cancer drugs, and medications for diabetes, cardiovascular diseases, and pain management. The company has gained a reputation for developing innovative and effective medications and has established close collaborations with renowned research institutions and pharmaceutical companies to constantly develop new products. In the dietary supplement sector, Hubei Minkang Pharmaceutical Ltd has developed products aimed at promoting general well-being and health. These products are based on natural ingredients and tailored to the needs of specific target groups, including supplements for pregnant and lactating women, immune system support, memory enhancement, and anti-aging products. The company has made efforts to present its products in carefully designed packaging to reinforce consumer trust in the quality and efficacy of the products. The sale of Hubei Minkang Pharmaceutical Ltd's products is conducted through various channels, including online shops and government-sponsored pharmacies. Overall, Hubei Minkang Pharmaceutical Ltd strives to meet the highest standards of quality in its products and services. The company is certified according to the international standard for quality management systems ISO 9001 and is committed to adhering to the rules and regulations of Good Manufacturing Practice (GMP). These efforts have helped Hubei Minkang Pharmaceutical Ltd become a trusted partner for customers and partners in China and internationally. In summary, the business model of Hubei Minkang Pharmaceutical Ltd is focused on developing and producing high-quality medications and dietary supplements that improve people's lives. The company has established itself as a leading manufacturer in China and aims to continuously develop new products and innovations to meet and exceed customer expectations.

What is the Hubei Minkang Pharmaceutical dividend?

Hubei Minkang Pharmaceutical pays a dividend of 0 USD distributed over payouts per year.

How often does Hubei Minkang Pharmaceutical pay dividends?

The dividend cannot currently be calculated for Hubei Minkang Pharmaceutical or the company does not pay out a dividend.

What is the Hubei Minkang Pharmaceutical ISIN?

The ISIN of Hubei Minkang Pharmaceutical is US44352W1018.

What is the Hubei Minkang Pharmaceutical ticker?

The ticker of Hubei Minkang Pharmaceutical is HBMK.

How much dividend does Hubei Minkang Pharmaceutical pay?

Over the past 12 months, Hubei Minkang Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hubei Minkang Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of Hubei Minkang Pharmaceutical?

The current dividend yield of Hubei Minkang Pharmaceutical is .

When does Hubei Minkang Pharmaceutical pay dividends?

Hubei Minkang Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hubei Minkang Pharmaceutical?

Hubei Minkang Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of Hubei Minkang Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hubei Minkang Pharmaceutical located?

Hubei Minkang Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hubei Minkang Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hubei Minkang Pharmaceutical from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Hubei Minkang Pharmaceutical pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Hubei Minkang Pharmaceutical in the year 2023?

In the year 2023, Hubei Minkang Pharmaceutical distributed 0 USD as dividends.

In which currency does Hubei Minkang Pharmaceutical pay out the dividend?

The dividends of Hubei Minkang Pharmaceutical are distributed in USD.

All fundamentals about Hubei Minkang Pharmaceutical

Our stock analysis for Hubei Minkang Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hubei Minkang Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.